Transferrin-Conjugated Nanostructured Lipid Carriers for Targeting Artemisone to Melanoma Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25169119 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Njoud Altuwaijri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Department, MCPHS University, 179 Longwood Ave, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Transferrin, Melanoma, Drug Carriers, Artemisinins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We report a successful formulation of Artemisone (ATM) in transferrin (Tf)-conjugated nanostructured lipid carriers (NLCs), achieving nearly a five-times increase in cell toxicity. The escalating cost of new drug discoveries led to the repurposing of approved drugs for new indications. This study incorporated Artemisone, an antimalarial drug, into a nanostructured lipid carrier (NLC) and tested for possible anticancer effects. The aim was to develop NLCs, and transferrin-conjugated NLCs (NLC-Tf) encapsulating Artemisone to enhance its delivery and anticancer activity. NLC formulations were prepared using high-pressure homogenization followed by ultrasonication and were characterized by particle size, zeta potential, and PDI. The conjugation of (Tf) to (NLC) was confirmed using IR, and the anticancer activity was tested using MTS assay. All formulations were in the nanometer size range (140–167 nm) with different zeta potential values. IR spectroscopy confirmed the successful conjugation of transferrin to NLC. Upon testing the formulations on melanoma cell lines using MTS assay, there was a significant decrease in viability and an increase in the encapsulated ATM-Tf toxicity compared to positive control ATM. The NLCs presented a promising potential carrier for delivering ATM to melanoma cells, and further conjugation with Tf significantly improved the ATM cytotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Department, MCPHS University, 179 Longwood Ave, Boston, MA 02115, USA.
- Pharmacy College, West Coast University, 590 N Vermont Ave, Los Angeles, CA 90005, USA.
ORCID-Profile: Njoud Altuwaijri, Eman Atef
Zitieren
APA
Altuwaijri, N., & Atef, E. (2024). Transferrin-Conjugated Nanostructured Lipid Carriers for Targeting Artemisone to Melanoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25169119
Vancouver
Altuwaijri N, Atef E. Transferrin-Conjugated Nanostructured Lipid Carriers for Targeting Artemisone to Melanoma Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25169119
BibTeX
@article{Altuwaijri2024,
author = {Altuwaijri, Njoud and Atef, Eman},
title = {Transferrin-Conjugated Nanostructured Lipid Carriers for Targeting Artemisone to Melanoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25169119}
}
EUVIMED